Dr Adam Hartley Consultant cardiologist
- Patient age group
- Adults
- Consultant registered on
- 22/07/2013
- Primary medical qualifications
- MBBS MRCP PhD
- Gender
- Male
- Services
- Hospitals
Background
Dr Adam Hartley MBBS PhD BSc(Hons) MRCP(UK) DIC PGCert is a consultant cardiologist specialising in coronary and structural intervention at Imperial College Healthcare NHS Trust and an honorary clinical lecturer in cardiovascular sciences at the National Heart and Lung Institute (NHLI), Imperial College London.
He completed his undergraduate training at Guy's, King's and St Thomas' Medical School in 2013, achieving all distinctions. This included an intercalated BSc in pharmacology for which he was awarded 1st class honours and the 'Best Intercalating Student in Pharmacology Award'. He was also awarded a scholarship from the British Heart Foundation.
He undertook his general medical training 2013-2016 in North West London, which included training in cardiology, heart and lung transplantation as well as respiratory medicine.
Dr Hartley was awarded a merit for completing a post graduate certificate in medical education from Cardiff University in 2016.
He was appointed as a National Institute for Health Research academic clinical fellow in cardiology at Imperial College London and specialist registrar at Imperial College Healthcare NHS Trust 2017-2019, during which time he completed his general cardiology training.
Dr Hartley has completed a PhD in cardiovascular sciences in the NHLI, Imperial College London, which focused on the prediction, detection and treatment of atherosclerotic plaques that are at high risk of future rupture and the culprit for heart attacks. His research was supported by a prestigious Wellcome Trust PhD Fellowship. Amongst other accolades, he was awarded a Basic Science Registration Grant from the European Society of Cardiology, as well as being a finalist for the British Cardiovascular Intervention Society Young Investigator Award and Royal Society of Medicine Cardiology President’s Prize.
Expertise
Coronary artery disease, angina, acute coronary syndromes (heart attacks), aortic stenosis, valvular heart disease
Research & publications
Dr Hartley's research interests include coronary artery disease, vulnerable atherosclerotic prone to rupture as well as structural heart interventions
A snapshot of his prominent research can be found here:
Hartley A., Marshall DC., Salciccioli JD., Sikkel MB., Maruthappu M., Shalhoub J. Trends in Mortality from Ischaemic Heart Disease and Cerebrovascular Disease in Europe: 1980-2009. 2016. Circulation. PMID: 27006480. https://www.ahajournals.org/doi/full/10.1161/circulationaha.115.018931
Hartley A., Haskard D., Khamis R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy. 2019. Trends Cardiovasc Med. PMID: 29934015. https://www.sciencedirect.com/science/article/pii/S1050173818300835
Kaura A., Hartley A. et al. The mortality risk prediction of mildly elevated high-sensitivity C-reactive protein beyond troponin in 102337 patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative CRP-RISK Study): A retrospective cohort study. 2022. PLoS Medicine. PMID: 35192610. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003911
Alshahrani N., Hartley A. et al. Remote Acute Assessment of Cardiac Patients Post-Acute Coronary Syndrome (TELE-ACS): A Randomized Controlled Trial. 2024. JACC. PMID: 38588928. https://www.jacc.org/doi/abs/10.1016/j.jacc.2024.03.398
Hartley A. et al. Trends in Mortality from Aortic Stenosis in Europe: 2000–2017. 2021. Front Cardiovasc Med. PMID: 34708094. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.748137/full
Alexiadou K., Hartley A., et al. The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action. 2024. Trends Cardiovasc Med. PMID: 38555029. https://www.sciencedirect.com/science/article/pii/S1050173824000197
Hartley A. et al. Size matters in atrial fibrillation: the underestimated importance of reduction of contiguous electrical mass underlying the effectiveness of catheter ablation. 2021. Europace. PMID: 33948648. https://academic.oup.com/europace/article/23/11/1698/6264888?login=false
Hartley A. et al. Anti-malondialdehyde low-density lipoprotein antibody levels predict low-attenuation plaque in the SCOT-HEART trial. 2024. JACC: Cardiovascular Imaging. PMID: 37656117. https://www.sciencedirect.com/science/article/pii/S1936878X23003480?via%3Dihub
Hajhosseiny R., Hartley A., et al. Free-breathing, non-contrast, 3D whole-heart coronary MRI for the identification of culprit and vulnerable atherosclerotic plaque. 2025. J Cardiovasc Magn Reson. PMID: 40274104.
https://www.sciencedirect.com/science/article/pii/S1097664725000602?via%3Dihub